Jutta Deckert
Vice President - Research & Development Iksuda Therapeutics
Jutta Deckert has more than 20 years of industry experience in oncology drug development with a focus on translational medicine. Currently serving as VP of Research & Development at Iksuda Therapeutics, Jutta leads the strategy and implementation of the company’s ADC pipeline, overseeing research, preclinical, and clinical activities for the advancement of novel ADC therapeutic candidates. She began her career in the ADC field at ImmunoGen, where she successfully transitioned multiple compounds into clinical development, including CD38-targeting isatuximab (approved for treating multiple myeloma) and an CD37-targeting ADC, naratuximab emtansine, for the treatment of B-cell malignancies.
Seminars
As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumor targets, understanding how bioconjugate design contributes and accumulates to performance in the clinic is vital to set up your therapy for success.
Take part in this workshop exploring recent case-study examples to contextualize and understand the performance of different ADC designs to understand what really makes a clinically effective ADC.
Workshop highlights include:
- Accurately correlating and characterizing antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
- Delving into ADC clinical case studies to evaluate differentiated design impact on safety and efficacy profiles to understand what makes a clinically effective ADC
- Finding the right match: Optimizing ADC design to improve payload target pairing
